243 related articles for article (PubMed ID: 18289690)
1. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.
Casini A; Guerri A; Gabbiani C; Messori L
J Inorg Biochem; 2008; 102(5-6):995-1006. PubMed ID: 18289690
[TBL] [Abstract][Full Text] [Related]
2. Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.
Casini A; Hartinger C; Gabbiani C; Mini E; Dyson PJ; Keppler BK; Messori L
J Inorg Biochem; 2008 Mar; 102(3):564-75. PubMed ID: 18177942
[TBL] [Abstract][Full Text] [Related]
3. ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme.
Casini A; Mastrobuoni G; Temperini C; Gabbiani C; Francese S; Moneti G; Supuran CT; Scozzafava A; Messori L
Chem Commun (Camb); 2007 Jan; (2):156-8. PubMed ID: 17180231
[TBL] [Abstract][Full Text] [Related]
4. Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c.
Casini A; Gabbiani C; Mastrobuoni G; Pellicani RZ; Intini FP; Arnesano F; Natile G; Moneti G; Francese S; Messori L
Biochemistry; 2007 Oct; 46(43):12220-30. PubMed ID: 17924668
[TBL] [Abstract][Full Text] [Related]
5. The x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteins.
Casini A; Temperini C; Gabbiani C; Supuran CT; Messori L
ChemMedChem; 2010 Dec; 5(12):1989-94. PubMed ID: 20931644
[No Abstract] [Full Text] [Related]
6. Interaction of anticancer ruthenium compounds with proteins: high-resolution X-ray structures and raman microscopy studies of the adduct between hen egg white lysozyme and AziRu.
Vergara A; D'Errico G; Montesarchio D; Mangiapia G; Paduano L; Merlino A
Inorg Chem; 2013 Apr; 52(8):4157-9. PubMed ID: 23517183
[TBL] [Abstract][Full Text] [Related]
7. Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.
Hartinger CG; Groessl M; Meier SM; Casini A; Dyson PJ
Chem Soc Rev; 2013 Jul; 42(14):6186-99. PubMed ID: 23660626
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.
Casini A; Mastrobuoni G; Terenghi M; Gabbiani C; Monzani E; Moneti G; Casella L; Messori L
J Biol Inorg Chem; 2007 Nov; 12(8):1107-17. PubMed ID: 17680283
[TBL] [Abstract][Full Text] [Related]
9. Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B.
Mura P; Camalli M; Casini A; Gabbiani C; Messori L
J Inorg Biochem; 2010 Feb; 104(2):111-7. PubMed ID: 19939460
[TBL] [Abstract][Full Text] [Related]
10. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
[TBL] [Abstract][Full Text] [Related]
11. Interactions between anticancer trans-platinum compounds and proteins: crystal structures and ESI-MS spectra of two protein adducts of trans-(dimethylamino)(methylamino)dichloridoplatinum(II).
Messori L; Marzo T; Michelucci E; Russo Krauss I; Navarro-Ranninger C; Quiroga AG; Merlino A
Inorg Chem; 2014 Aug; 53(15):7806-8. PubMed ID: 25025479
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme.
Messori L; Merlino A
Dalton Trans; 2014 Apr; 43(16):6128-31. PubMed ID: 24553967
[TBL] [Abstract][Full Text] [Related]
13. Reactions of cytotoxic metallodrugs with lysozyme in pure DMSO explored through UV-Vis absorption spectroscopy and ESI MS.
Marzo T; Savić A; Massai L; Michelucci E; Sabo TJ; Grguric-Šipka S; Messori L
Biometals; 2015 Apr; 28(2):425-30. PubMed ID: 25715906
[TBL] [Abstract][Full Text] [Related]
14. The mode of action of anticancer gold-based drugs: a structural perspective.
Messori L; Scaletti F; Massai L; Cinellu MA; Gabbiani C; Vergara A; Merlino A
Chem Commun (Camb); 2013 Oct; 49(86):10100-2. PubMed ID: 24045294
[TBL] [Abstract][Full Text] [Related]
15. ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes.
Casini A; Mastrobuoni G; Ang WH; Gabbiani C; Pieraccini G; Moneti G; Dyson PJ; Messori L
ChemMedChem; 2007 May; 2(5):631-5. PubMed ID: 17366652
[No Abstract] [Full Text] [Related]
16. Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.
Groessl M; Tsybin YO; Hartinger CG; Keppler BK; Dyson PJ
J Biol Inorg Chem; 2010 Jun; 15(5):677-88. PubMed ID: 20213306
[TBL] [Abstract][Full Text] [Related]
17. CE in anticancer metallodrug research--an update.
Hartinger CG; Keppler BK
Electrophoresis; 2007 Oct; 28(19):3436-46. PubMed ID: 17847132
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
[TBL] [Abstract][Full Text] [Related]
19. Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme.
Gabbiani C; Massai L; Scaletti F; Michelucci E; Maiore L; Cinellu MA; Messori L
J Biol Inorg Chem; 2012 Dec; 17(8):1293-302. PubMed ID: 23132507
[TBL] [Abstract][Full Text] [Related]
20. Chemo-genetic optimization of DNA recognition by metallodrugs using a presenter-protein strategy.
Zimbron JM; Sardo A; Heinisch T; Wohlschlager T; Gradinaru J; Massa C; Schirmer T; Creus M; Ward TR
Chemistry; 2010 Nov; 16(43):12883-9. PubMed ID: 20878805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
